All News

The study is intended to support potential label expansion of testosterone undecanoate in men ages 65 to 80 with hypogonadism.

Enolen is currently under investigation in a phase 1 trial to assess its safety and efficacy in delivering enzalutamide locally into the prostate.

The phase 2 PROHEAR trial is assessing the safety and efficacy of ACOU085 in preventing ototoxic hearing loss induced by cisplatin-based chemotherapy.

The results from this study are expected to support an application to the FDA for pre-market approval of the Butterfly device.

2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.

This episode delivers an empowering, forward-looking conversation on how APPs and physicians alike can lead health care transformation.

The study is being conducted as part of the landmark ProtecT trial.

Heidegger emphasizes that sexual concerns are almost never purely biological or purely psychological—they are biopsychosocial.

The code, J9282, went into effect on January 1, 2026.

"Although social media may not be for every health care worker, I hope that moving forward, more medical content creators will collaborate with the academic medical community to shape the world for the better," writes Maheetha Bharadwaj, MD.

A recap of the FDA submissions and regulatory decisions in urology from December 2025.

In this episode, Jeremy Y.C. Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery), joins host Adam Weiner, MD, to discuss en bloc vs standard transurethral resection of bladder tumor in NMIBC.

As the year comes to a close, we revisit some of this year’s top content in female urology.

As the year comes to a close, we revisit some of this year’s top content in men's health.

As the year comes to a close, we revisit some of this year’s top content on bladder cancer.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.

As the year comes to a close, we revisit some of this year’s top content on genomic testing.

As the year comes to a close, we revisit some of the top Urology Times podcast episodes from 2025.

Joshua Palka, DO, reflects on the key trends that shaped urologic oncology in 2025, emphasizing the growing role of precision medicine across disease states.

As the year comes to a close, we revisit some of this year’s top content on urology coding and reimbursement.

Kenneth G. Nepple, MD, discusses a quality improvement initiative focused on identifying patients with prostate cancer who may be eligible for genetic testing.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

In this episode, Timothy Daskivich, MD, joins host Adam Weiner, MD, to discuss survivorship and long-term quality-of-life considerations in prostate cancer care.

"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.

The application is supported by results from the phase 3 PIVOT-PO trial.

The PROSTOX ultra test identifies men with localized prostate cancer who are at a higher risk of developing late GU toxicity from radiation, helping to inform treatment decisions.